NVO News and Press, Novo Nordisk A/S From 05/29/24

2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...

2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...

2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...

2024-05-29 10:18:39 ET More on Novo Nordisk, Catalent Catalent - Novo Holdings Merger: Attractive Spread Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Consid...

2024-05-29 09:25:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...

2024-05-28 21:19:27 ET Summary Chase Coleman's Tiger Global Management 13F portfolio value increased from $14.1B to $18.3B this quarter. The largest five positions in the portfolio are Meta Platforms, Microsoft, Alphabet, Apollo Global, and Amazon.com. New stakes include Liber...

2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...

2024-05-28 14:36:30 ET Summary Calamos Global Dynamic Income Fund offers high-income and geographic diversification, without sacrificing equity exposure. The fund's distribution yield of 9.00% is lower than its peers, but it has delivered strong recent performance and total return...

2024-05-28 12:02:07 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Who will launch the next bi...

2024-05-28 08:30:00 ET Summary Novo Nordisk stock has easily outperformed the market over the past year. Novo Nordisk's growth potential through its weight loss drugs is expanding. Competition from rivals like Eli Lilly and Amgen could impact demand and pricing dynamics in the...